title: Altered metabolism in the ex vivo remnant kidney. II. Effects of metabolic inhibitors and dietary protein.
abstract: To understand further the contribution of heightened net sodium reabsorption (TNa+) and other nontransport processes to increased and altered metabolic activity of the rat remnant kidney (RK), isolated RK and normal kidneys (NK) were perfused with and without metabolic inhibitors and following 4 weeks of low (12%)- or high (40%)-protein diet. 3-Mercaptopicolinate (200 microM) and 2-deoxyglucose (200 microM) reduced glucose production and consumption, respectively, without altering oxygen consumption (QO2). Ouabain reduced TNa+ and QO2 in NK but not RK, and increased glucose consumption in RK (by 67%, p < 0.02, n = 12) and NK (by 54%, p < 0.05, n = 12). Raising perfusate pH by 0.3 U to 7.65 increased glucose production in RK but not NK and reduced TNa+ in NK but not RK. Dietary protein restriction reduced QO2 (2.18 +/- 0.29 vs. 4.13 +/- 0.20 mumol-1 x min-1 x g-1, p < 0.001), TNa+ (8.74 +/- 4.39 vs. 38.83 +/- 8.32, p < 0.01) and ammoniagenesis (0-30 min, 0.16 +/- 0.05 vs. 0.32 +/- 0.10, p < 0.05) in RK, but not NK. In summary: (1) responses to ouabain and alkalosis, but not other metabolic inhibitors, were quite distinct in remnant versus normal kidneys, and (2) protein restriction limited sodium-transport-dependent and -independent hypermetabolism in RK.
authors.affiliation: Department of Renal Medicine, Westmead Hospital, N.S.W., Australia.
authors.forename: D C
authors.initials: DC
authors.lastname: Harris
authors.forename: C
authors.initials: C
authors.lastname: Tay
mesh_terms: D000471:Alkalosis / Q000378:metabolism; D000641:Ammonia / Q000378:metabolism; D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D003513:Cycloheximide / Q000494:pharmacology; D003847:Deoxyglucose / Q000494:pharmacology; D004044:Dietary Proteins / Q000494:pharmacology*; D004852:Epoxy Compounds / Q000494:pharmacology; D005227:Fatty Acids / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D007668:Kidney / Q000378:metabolism*; D008297:Male; D009392:Nephrectomy; D009399:Nephrons / Q000187:drug effects / Q000378:metabolism; D010042:Ouabain / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000037:antagonists & inhibitors; D010848:Picolinic Acids / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000378:metabolism
chemical_list: D000963:Antimetabolites; D004044:Dietary Proteins; D004852:Epoxy Compounds; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D010848:Picolinic Acids; D010042:Ouabain; D000641:Ammonia; C008363:3-mercaptopicolinic acid; D003513:Cycloheximide; D003847:Deoxyglucose; D012964:Sodium; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D005947:Glucose; C021756:2-tetradecylglycidic acid